Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Partnering With Jooble

Advertising

The Latest Pharma Jobs, News and Events

pharmiweb.com today | 17 January 2019

Luye Pharma Reaches Strategic Partnership with AstraZeneca, Strengthens Commitment to Cardiovascular Therapeutic Field

Luye Pharma has announced it has entered an agreement with AstraZeneca China, the terms of which grant AstraZeneca China exclusive rights to promote Luye Pharma's Xuezhikang Capsules in mainland China. This is the first time that a multinational pharmaceutical company has gained exclusive authorization in China to promote an innovative drug independently developed by a Chinese pharmaceutical company....

According to the agreement, AstraZeneca will be responsible for the exclusive promotion of Xuezhikang Capsules in mainland China, while Luye Pharma will retain asset rights, commercial sales rights, the registration permit, all intellectual property rights and other product-related rights aside from product promotion.

As a widely acknowledged product both at home and abroad, Xuezhikang is the only natural lipid-regulating drug with proven benefits in clinical endpoints, and has completed phase II clinical trials in compliance with U.S. FDA regulations. Large-scale and evidence-based clinical studies, including the China Coronary Secondary Prevention Study (CCSPS) have confirmed that Xuezhikang, with comparatively few adverse reactions, can inhibit cholesterol synthesis and significantly reduce total mortality, coronary heart disease mortality and the incidence of cardiovascular events in patients with coronary heart disease. Clinical trials results of Xuezhikang combined with Ezetimibe also revealed that Xuezhikang, whether in monotherapy or used in combination with Ezetimibe, can significantly reduce low-density lipoprotein cholesterol (LDL-C), with a 45% reduction in LDL-C observed in combination treatment. Xuezhikang also demonstrated a strong safety profile with no serious liver and muscle-related adverse events and no increased risk of new-onset diabetes reported in clinical use. Additionally, it was learned Xuezhikang contains a variety of beneficial components that can also reduce blood lipid levels and protect cardiovascular health, and is therefore safe for long-term use.

Given their proven efficacy and safety in lipid-regulation, Xuezhikang Capsules have been recommended as a first-line blood lipid management drug by the Chinese Guidelines for the Prevention and Treatment of Adults with Dyslipidemia (2016 Revision), and included in the latest edition of China's National Drug Catalog for Basic Medical Insurance and Work-Related Injury Insurance, as well as the country's National Essential Drugs List.

Under the partnership, Luye Pharma will leverage AstraZeneca's long-term expertise in the cardiovascular therapeutic field, both in terms of its excellent academic promotion and extensive distribution network, further expanding the accessibility of Xuezhikang Capsules in China for the benefit of more patients with cardiovascular diseases. It is expected that Xuezhikang Capsules will maintain a double-digit compound annual growth rate in sales over the next 10 years, significantly higher than the

show more

Latest Poll

If you are considering a job change, what are the main reasons?

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.